Diabetic Cardiovascular Autonomic Neuropathy: Effects of Simvastatin and Omega-3 Polyunsaturated Fatty Acids on Insulin Resistance and Lipid Profile Parameters

Introduction. Currently, there is no unified treatment algorithm of cardiac autonomic neuropathy (CAN) in patients with type 2 diabetes mellitus (T2DM). The aim the study was to investigate effects simvastatin (SIM) and -3 polyunsaturated fatty acids (-3 PUFAs) on blood lipid profile insulin resistance (IR) definite neuropathy. Materials methods. involved 72 T2DM CAN. Patients were divided into four groups: 1st - received standard hypoglycemic therapy control (n = 15); 2nd 22) – addition 20.0 mg/q.d.; 3rd 18) 1 capsule/q.d. ω-3 PUFAs; 4th 17) SIM 10.0 mg/q.d capsule/q.d PUFAs for three months. concentration glucose, glycated hemoglobin A1c, immunoreactive (IRI), total cholesterol (TC), low-density lipoprotein (LDL-C), high-density (HDL-C), triglycerides (TG) determined. Homeostasis model assessment IR (HOMA-IR), atherogenic coefficient (AC), TG/LDL-C, TG/TC, TG/LDL-C TG glucose index (TyG) calculated. Results. Prescription accompanied by a statistically significant decrease TC, LDL-C, concentrations. In parallel, induced AC, TG/HDL-C, increase HDL-C, does not affect IRI, HOMA-IR, TC/LDL-C/HDL-C, TyG. use has contributed reduction TG, TyG index, changes IRI content, TC/LDL-C/HDL-C. combined prescription more pronounced, spectrum, as well HOMA-IR. Conclusions. Obtained results justify appropriateness Keywords: mellitus, neuropathy, treatment.